Congestive Heart Failure Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Beta Blockers, ACE Inhibitors, Angiotensin Receptor Blockers, Diuretics, Inotropic Agents, Aldosterone Antagonist, Calcium Channel Blockers, Others), By Route Of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region Forecast 2019-2030

Congestive heart failure treatment market size was valued at US$ 19.5 billion in 2023, and it is expected to reach a value of US$ 31.72 billion by 2030, growing with a CAGR of 7.2% from 2024-2030. At present, the treatment of congestive heart failure relies on a range of medications, including angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Additionally, various other therapeutic approaches are employed, such as aldosterone antagonists, amiodarone, antiplatelet agents, anticoagulants, calcium channel blockers, diuretics, and nitrates, among others, to address the needs of patients with heart failure.

Congestive heart failure is a chronic and progressive condition that affects the pumping capacity of heart muscles and also referred as heart failure. Congestive heart failure can refer to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Ventricles pump blood to your body's organs and tissues, and the atria receive blood from your body as it circulates back from the rest of your body.

Congestive heart failure develops when ventricles unable to pump sufficient volume of blood to the body. Eventually, blood and other fluids can back up inside your lungs, liver, abdomen, and lower body. There are two types of congestive heart failure, they are systolic heart failure and diastolic heart failure. Many generic manufacturers foray into the market due to patent expirations of CHF innovators drugs. The presence generics expected to hinder the market revenue and may hamper the uptake of new and expected novel drugs. Increase in prevalence of cardiovascular diseases across regions is one the major factors expected to drive the revenue growth of congestive heart failure treatment globally. Lifestyle related factors are expected to add to growing disease incidence of CVDs. In addition growing number of obese patients are expected to bolster the market. Congestive heart failure is a common condition, especially among older adults. In the United States, it's estimated that around 6.2 million adults have heart failure.

Key Developments

• In July 2015, U.S. Food and Drug Administration (FDA) approved Novartis, Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to treat heart failure patients with reduced ejection fraction.
• In April 2015, Amgen received U.S. FDA approval for its Corlanor (ivabradine) to treat of heart failure conditions.